Literature DB >> 8020137

Mutational spectrum in the p53 gene in bladder tumors from the endemic area of black foot disease in Taiwan.

A Shibata1, P F Ohneseit, Y C Tsai, C H Spruck, P W Nichols, H S Chiang, M K Lai, P A Jones.   

Abstract

An elevated risk of bladder cancer has been reported in the endemic region of 'black foot disease' on the southwest coast of Taiwan and may be related to high arsenic levels in artesian well water. Thirteen urothelial tumors from this endemic region were examined for mutations in exons 5-8 of the p53 gene to identify the effects of possible exogenous factors at the DNA level. DNA was extracted from archival tissue after microdissection of tumors and analyzed by PCR-SSCP (polymerase chain reaction-based single strand conformation polymorphism), followed by direct sequencing. Eight cases (62%) showed mutations and 9 of the 10 point mutations observed were transitions. The type and position of the mutations were not significantly different when compared with the spectra of p53 mutations previously reported for transitional cell carcinomas (TCCs). However, two of the mutations were CGC-->CAC base changes at codon 175, a mutational hotspot for many tumor types but previously unreported in TCCs except in cases associated with inflammatory agents. Three of the tumors examined were found to contain double mutations, a relatively rare mutagenic event in human cancers. Our results suggest that the agents responsible for the high risk of bladder cancer in the black foot disease region may operate through an inflammation-based mechanism which increases the amount of DNA damage per mutagenic event.

Entities:  

Mesh:

Year:  1994        PMID: 8020137     DOI: 10.1093/carcin/15.6.1085

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  9 in total

Review 1.  Chemoprevention of bladder cancer.

Authors:  Dragan J Golijanin; David Kakiashvili; Ralph R Madeb; Edward M Messing; Seth P Lerner
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

2.  Clinicopathological features of bladder cancer associated with chronic exposure to arsenic.

Authors:  N H Chow; Y L Guo; J S Lin; J H Su; T S Tzai; H R Guo; I J Su
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  P53 mutations associated with breast, colorectal, liver, lung, and ovarian cancers.

Authors:  T Lasky; E Silbergeld
Journal:  Environ Health Perspect       Date:  1996-12       Impact factor: 9.031

4.  Chronic arsenic exposure and risk of infant mortality in two areas of Chile.

Authors:  C Hopenhayn-Rich; S R Browning; I Hertz-Picciotto; C Ferreccio; C Peralta; H Gibb
Journal:  Environ Health Perspect       Date:  2000-07       Impact factor: 9.031

5.  Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan.

Authors:  C H Hsu; S A Yang; J Y Wang; H S Yu; S R Lin
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

Review 6.  Arsenic Disruption of DNA Damage Responses-Potential Role in Carcinogenesis and Chemotherapy.

Authors:  Clarisse S Muenyi; Mats Ljungman; J Christopher States
Journal:  Biomolecules       Date:  2015-09-24

7.  Loss of heterozygosity in (LewisxF344)F1 rat urinary bladder tumors induced with N-butyl-N-(4-hydroxybutyl)nitrosamine followed by dimethylarsinic acid or sodium L-ascorbate.

Authors:  T Chen; Y Na; H Wanibuchi; S Yamamoto; C C Lee; S Fukushima
Journal:  Jpn J Cancer Res       Date:  1999-08

8.  Unventilated indoor coal-fired stoves in Guizhou province, China: cellular and genetic damage in villagers exposed to arsenic in food and air.

Authors:  Aihua Zhang; Hong Feng; Guanghong Yang; Xueli Pan; Xianyao Jiang; Xiaoxin Huang; Xuexin Dong; Daping Yang; Yaxiong Xie; Luo Peng; Li Jun; Changjun Hu; Li Jian; Xilan Wang
Journal:  Environ Health Perspect       Date:  2007-01-09       Impact factor: 9.031

9.  Analysis of p53, p16MTS, p21WAF1 and H-ras in archived bladder tumours from workers exposed to aromatic amines.

Authors:  T Sørlie; G Martel-Planche; P Hainaut; J Lewalter; R Holm; A L Børresen-Dale; R Montesano
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.